John Moore, MD
Urology · Little Rock, ARNPI 1669615225
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.3%), other and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Angiodynamics, Inc. at 48.8% of the total. 2025 is the largest year on record at $11,785, more than ten times the $683 reported in 2019.
Across 354 payments — averaging $54.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$9K
- Axonics, Inc.$2K
- Boston Scientific$2K
- Teleflex LLC$1K
- AbbVie$806
- Astellas Pharma US Inc$672
- plus $3K from 22 others
Across 146 payments — averaging $744.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axonics, Inc.$47K
- Medtronic$41K
- Urovant Sciences Inc$11K
- Sumitomo Pharma America, Inc.$6K
- Janssen Research & Development, LLC$3K
What the payments were for
- Travel & lodging$4,66024%
- Food & beverage$8,33743%
- Education$900%
- Other$6,16732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 25 | $9,406 |
| Axonics, Inc. | 90 | $2,423 |
| Boston Scientific | 13 | $2,008 |
| Teleflex LLC | 10 | $1,052 |
| AbbVie(2 entities) | 52 | $806 |
| Astellas Pharma US Inc | 38 | $672 |
| Medtronic(2 entities) | 27 | $432 |
| Agiliti Surgical, Inc. | 2 | $285 |
| Pfizer | 12 | $278 |
| Johnson & Johnson | 9 | $266 |
| Novartis | 10 | $200 |
| Myovant Sciences Inc. | 12 | $187 |
| Dendreon Pharmaceuticals LLC | 7 | $165 |
| Profound Medical Corp. | 1 | $143 |
| Valencia Technologies Corporation | 3 | $126 |
| Amgen | 6 | $106 |
| Tolmar, Inc. | 5 | $101 |
| Urogen Pharma, Inc. | 4 | $87 |
| Blue Earth Diagnostics | 5 | $84 |
| Myriad Genetic Laboratories, Inc. | 5 | $83 |
| Antares Pharma, Inc. | 4 | $83 |
| Merck | 3 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| Bayer | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 2 | $49 |
| Travere Therapeutics, Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$9,070
- Lumenis Pulse 120H$1,589
- UroLift$873
- Axonics$644
- Bulkamid$531
- Axonics r-SNM System$234
- Sonablate HIFU$190
- Koelis Trinity MRI/US Fusion$190
- Erleada$156
- Tulsa-Pro$143
- INTERSTIM$123
- XTANDI$109
How this compares
$19,254 in reported general payments places this provider in the 75th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $199,948 |
| OrgovyxRelugolix | 62 | $162,727 |
| Lupron DepotLeuprolide Acetate | 21 | $126,786 |
| GemtesaVibegron | 66 | $33,706 |
| MyrbetriqMirabegron | 57 | $32,132 |
| Tamsulosin Hcl | 939 | $9,158 |
| Oxybutynin Chloride ErOxybutynin Chloride | 598 | $9,032 |
| Estradiol | 137 | $8,511 |
| Solifenacin Succinate | 118 | $3,848 |
| Finasteride | 348 | $3,148 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 34 | $2,250 |
| Cephalexin | 306 | $1,905 |
| Ciprofloxacin Hcl | 364 | $1,498 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 174 | $1,393 |
| NitrofurantoinNitrofurantoin Macrocrystal | 58 | $1,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $672 | $232,08071 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $53 | $196,433128 claims |
| AbbVieLupron Depot | $806 | $126,78621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 88 urology providers in Arkansas.
Other urology in Little Rock
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
- Timothy LangfordLittle Rock$133K
- Kevin ClaybrookLittle Rock$132K
- Gail JonesLittle Rock$128K
- Michael ChildsLittle Rock$8K
- Bruno Lopes Cancado MachadoLittle Rock$7K
- Marcelo BigarellaLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.